Doctor Verena Karsten
Cambridge ()
Impact of patisiran on norfolk QOL-DN in patients with hereditary transthyretin-mediated amyloidosis: results from the cardiac subpopulation in the phase 3 apollo study
Event: Heart Failure 2018 & World Congress on Acute Heart Failure
Topic: Pharmacotherapy
Session: Patient management - From oral treatment to transplant
This platform is supported by
